Skip to main content
SpringerLink
Log in

The Combination Assay with Circulating Vascular Endothelial Growth Factor (VEGF)-C, Matrix Metalloproteinase-9, and VEGF for Diagnosing Lymph Node Metastasis in Patients With Non–Small Cell Lung Cancer

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The aim of the present study was to evaluate the diagnostic utility of levels of circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9 (MMP-9), and VEGF and to verify that the combination assay of these circulating factors is a clinically useful indicator to predict the presence of lymph node metastasis in non–small cell lung cancer (NSCLC).

Methods: A series of 78 patients who underwent surgery for NSCLC was used in this study. Serum VEGF-C and VEGF and plasma MMP-9 levels were analyzed with enzyme-linked immunosorbent assay (ELISA) kits. Logistic regression models were used to analyze the influence of VEGF-C, MMP, and VEGF levels on the probability of presence or absence of lymph node metastasis.

Results: Patients with lymph node metastasis had higher serum VEGF- C, VEGF, and plasma MMP-9 concentrations than did those without metastasis (VEGF-C, P = .0004; VEGF, P = .001). Serum VEGF- C reached a sensitivity of 85% and specificity of 68% when a cutoff value of 1762.0 pg/mL was applied, while VEGF reached 80% sensitivity and 59% specificity at 316.8 pg/mL. MMP-9 reached a sensitivity of 63% and specificity of 75% when a cutoff value of 51.4 ng/mL was applied. In the ROC curve analysis, VEGF-C (0.761) had the biggest areas under the ROC curve, followed by MMP-9 (0.723) and VEGF (0.694). Combination assay of three markers had higher sensitivity and specificity for prediction than single-marker assays (AUC = 0.837).

Conclusions: This study has confirmed that combination assay of three markers to determine VEGF-C, MMP-9, and VEGF expression in circulation detects lymph node metastasis in NSCLC with higher accuracy than single-marker assays.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Laack E, Köhler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13: 1550–7.

    Article  PubMed  CAS  Google Scholar 

  2. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001; 85: 255–60.

    Article  PubMed  CAS  Google Scholar 

  3. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe G. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and deceased nm 23 expression associated with microdissemination in the lymph nodes in stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119: 804–13.

    Article  PubMed  CAS  Google Scholar 

  4. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary non-small cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003; 98: 1217–22.

    Article  PubMed  CAS  Google Scholar 

  5. Tamura M, Ohta Y, Tsunezuka Y, et al. Chest computed tomography and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cel lung cancer. Chest 2004; 126: 342–6.

    Article  PubMed  CAS  Google Scholar 

  6. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995; 6: 1059–62.

    Google Scholar 

  7. Ohta Y, Watanabe Y, Murakami S, et al. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 1997; 76(8): 1041–5.

    PubMed  CAS  Google Scholar 

  8. Tamura M, Ohta Y, Kajita T, et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001; 8: 1097–102.

    PubMed  CAS  Google Scholar 

  9. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp Med 2001; 95: 1–4.

    Article  CAS  Google Scholar 

  10. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenic factors and matrix metalloproteinases upon tumor progression in non-small cell lung cancer. Br J Cancer 2001; 85: 1706–12.

    Article  PubMed  CAS  Google Scholar 

  11. Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5: 149–53.

    PubMed  CAS  Google Scholar 

  12. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52: 4589–49.

    Google Scholar 

  13. Ylisirnio S, Höyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20: 1311–6.

    PubMed  CAS  Google Scholar 

  14. Guan K, Ye H, Yan Z, Wang Y, Hou S. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003; 61: 719–24.

    Article  PubMed  Google Scholar 

  15. Faris E, Ranuncolo S, Cresta C, et al. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000; 89: 389–94.

    Article  Google Scholar 

  16. John M, Oltmanns U, Witt C, and Jung K. Re: elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp Med 2002; 96: 126–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General and Cardiothoracic Surgery, Kanazawa University School of Medicine, Kanazawa, Japan

    Masaya Tamura MD, Makoto Oda MD, Isao Matsumoto MD, Yoshio Tsunezuka MD, Kazuyuki Kawakami MD & Go Watanabe MD

  2. Department of Thoracic Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

    Yasuhiko Ohta MD

  3. Department of General and Cardiothoracic Surgery, Kanazawa University School of Medicine, Takara-machi 13–1, Kanazawa, 920–8641, Ishikawa, Japan

    Masaya Tamura MD

Authors
  1. Masaya Tamura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Oda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isao Matsumoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshio Tsunezuka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyuki Kawakami MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhiko Ohta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Go Watanabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaya Tamura MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamura, M., Oda, M., Matsumoto, I. et al. The Combination Assay with Circulating Vascular Endothelial Growth Factor (VEGF)-C, Matrix Metalloproteinase-9, and VEGF for Diagnosing Lymph Node Metastasis in Patients With Non–Small Cell Lung Cancer. Ann Surg Oncol 11, 928–933 (2004). https://doi.org/10.1245/ASO.2004.01.013

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.01.013

Key Words:

Search

Navigation